Crowe Lisa, Brown Morven C, Lecouturier Jan, Greystoke Alastair, Nuryunarsih Desy, Rimmer Ben, Bojke Andy, Bojke Rona, Richardson James, Wells Mary, Ezeala Ezinne, Carter Louise, Todd Adam, Sharp Linda
Population Health Sciences Institute, Newcastle University, Ridley 1 Building, Claremont Road, Newcastle Upon Tyne, NE1 7RU, UK.
Newcastle University Centre for Cancer, Newcastle University, Newcastle Upon Tyne, UK.
J Cancer Surviv. 2025 Apr 10. doi: 10.1007/s11764-025-01787-4.
Develop an instrument to assess unmet needs in cancer patients using immuno-, biological and precision (IBP) therapies.
Development followed COSMIN guidance. Instruments to assess unmet needs of advanced cancer patients were identified, and quality and content were evaluated in a systematic review (Phase 1). Semi-structured interviews with patients utilising IBP therapies (n = 31) and healthcare professionals (n = 22) explored supportive care needs (Phase 2). Phase 3 selected a base instrument to adapt, generated new items and iteratively refined these through six meetings involving professionals (n = 8) and public and patient involvement representatives (n = 9) and patient cognitive interviews (n = 16). Phase 4 piloted the new instrument (n = 50 patients).
Twenty-four instruments were identified; none was developed for patients utilising IBP therapies (Phase 1). Ten domains of unmet needs were identified from the interview data (Phase 2). SCNS-SF34 was selected as the base instrument. Informed by interview data, an "add-on module" (SCNS-TARGET) was developed for patients utilising IBP therapies comprising 25 questions (psychological domain, 7 items; information, 6; healthcare, 5; economic, 3; role, 2; physical, 1; social, 1; Phase 3). Levels of missingness were low; reliability varied across questions, and, on average, patients reported 7.40 (standard deviation = 8.43) unmet needs on SCNS-TARGET (Phase 4).
SCNS-TARGET is designed for use alongside SCNS-SF34 to assess unmet needs in those using IBP therapies. Content and face validity have been established.
SCNS-TARGET can help researchers and healthcare professionals determine unmet needs and inform requirements for new services and interventions, among patients using IBP therapies.
开发一种工具，用于评估癌症患者在使用免疫、生物和精准（IBP）疗法时未满足的需求。
开发过程遵循COSMIN指南。在系统评价中识别用于评估晚期癌症患者未满足需求的工具，并对其质量和内容进行评估（第1阶段）。对使用IBP疗法的患者（n = 31）和医疗保健专业人员（n = 22）进行半结构化访谈，以探讨支持性护理需求（第2阶段）。第3阶段选择一种基础工具进行改编，生成新的条目，并通过六次会议进行迭代完善，这些会议涉及专业人员（n = 8）、公众和患者参与代表（n = 9）以及患者认知访谈（n = 16）。第4阶段对新工具进行试点（n = 50名患者）。
识别出24种工具；没有一种是为使用IBP疗法的患者开发的（第1阶段）。从访谈数据中识别出未满足需求的10个领域（第2阶段）。选择SCNS-SF34作为基础工具。根据访谈数据，为使用IBP疗法的患者开发了一个“附加模块”（SCNS-TARGET），包括25个问题（心理领域，7项；信息，6项；医疗保健，5项；经济，3项；角色，2项；身体，1项；社会，1项；第3阶段）。缺失水平较低；可靠性因问题而异，平均而言，患者在SCNS-TARGET上报告7.40（标准差 = 8.43）项未满足的需求（第4阶段）。
SCNS-TARGET旨在与SCNS-SF34一起使用，以评估使用IBP疗法的患者未满足的需求。已确立内容效度和表面效度。
SCNS-TARGET可以帮助研究人员和医疗保健专业人员确定使用IBP疗法的患者未满足的需求，并为新服务和干预措施的要求提供信息。
